Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine therapy and neuropsychological function under stress in obsessive-compulsive disorder
2021-003228-34Phase 3Active
- Sponsor
- Medical University of Vienna
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ketamine in obsessive compulsive disorder (OCD), sponsored by Medical University of Vienna. Primary endpoints: Primary efficacy endpoint and Short-term symptom change (24 hours). Started Jan 2022; status: active.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2021-003228-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003228-34.